Form 4: Tectonic Therapeutic CFO Daniel Lochner Reports Stock and Option Awards

Chief Financial Officer Daniel Lochner of Tectonic Therapeutic, Inc. reports the acquisition of restricted stock units and stock options.

Summary

• On February 4, 2025, Daniel Lochner, the CFO of Tectonic Therapeutic, Inc., acquired 18,074 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest in three equal annual installments starting February 4, 2026, contingent upon continued service to the company.
• Lochner also acquired options to purchase 32,862 shares of common stock at an exercise price of $48.01.
• These options vest in 48 equal monthly installments beginning March 4, 2025, also subject to continued service.
• Following these transactions, Lochner directly owns 18,074 shares of common stock and options for 32,862 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, incentivizing long-term commitment. There are no immediate negative implications.

Positives

• The granting of stock options and restricted stock units to the CFO aligns his interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company's long-term success.

Risks

• The value of the stock options is dependent on the future performance of Tectonic Therapeutic's stock price.
• If Lochner leaves the company before the vesting dates, he will forfeit the unvested RSUs and options.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules suggest an expectation of continued employment and company performance.

Industry Context

Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies, often used to align management's interests with shareholder value.
• Vesting schedules, like the ones described, are typical to ensure long-term commitment from the executive.
• Comparable companies such as Amgen, Biogen, and Gilead Sciences also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates